Multifactorial intensive therapy (including statins) is insufficient to prevent the development or progression of microvascular disease (retinopathy, nephropathy, neuropathy) in up to 50 percent of patients with type 2 diabetes.
Atherogenic Dyslipidemia and Residual Vascular Risk
Atherogenic dyslipidemia is characterized by elevated TG and low levels of HDL-C.
In the past three decades in the U.S., while the prevalence of abnormal levels of LDL-C has decreased, the prevalence of combined abnormal TG (greater than or equal to 150 mg/dL) and HDL-C (<40 mg/dL) has doubled and the prevalence of elevated TG (greater than or equal to 150 mg/dL) has increased five-fold. Elevated TG (>150 mg/dL) is also common, affecting about 50 percent of adults with prior CVD.
Atherogenic dyslipidemia contributes to the increased risk of macrovascular events such as myocardial infarction and stroke, and may be implicated in microvascular complications such as diabetic eye, kidney and lower limb disease.
- Among patients achieving LDL-C <70 mg/dL with a statin, CVD risk is almost 60 percent greater for patients with TG >200 mg/dL - In patients achieving LDL-C <70 mg/dL with a statin, CV risk was higher in patients with a low HDL-C (HDL-C <37 mg/dL vs. those with a HDL-C >55 mg/dL)
The mission of R3i
To reduce the significant residual risk of macrovascular events and microvascular complications which persists in most patients despite current standards of care including achievement of low density lipoprotein goal and intensive control of blood pressure and blood glucose.
R3i board of trustees Professor Jean-Charles Fruchart, President Institut Pasteur de Lille Universite, Lille2,
|SOURCE Residual Risk Reduction Initiative Foundation|
Copyright©2009 PR Newswire.
All rights reserved